Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Key catalysts approach for Orphazyme, Gemini and Immutep.
But the company focused on a modified intent-to-treat analysis of its pivotal trial.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
A win for Vir’s late-to-the-game antibody and another fail for Roche with Actemra show how developers are still feeling their way in Covid-19.
And Gilead has plans for its biannual injection in pre-exposure prophylaxis, too.